Dermatology最新文献

{"title":"Diagnostic Accuracy of a Questionnaire Screening Test in Assessing the Prevalence of Hidradenitis Suppurativa in Sydney, Australia.","authors":"James Pham, Akshay Flora, Emily Kay Kozera, Cecilia E Medianfar, Dorra Bouazzi, Robin Christensen, Gregor B E Jemec, John W Frew","doi":"10.1159/000540455","DOIUrl":"10.1159/000540455","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.</p><p><strong>Methods: </strong>The methodology followed the previously published GHiSA methodology. A validated questionnaire was used to identify patients likely to have a diagnosis of HS. Screen-positive patients as well as a selection of screen-negative patients underwent clinical examination by a single physician experienced in the identification, diagnosis and management of HS to further validate the sensitivity and specificity of the questionnaire.</p><p><strong>Results: </strong>A total of 1,657 eligible healthy accompanying adults were approached, of whom 1,002 consented for inclusion in the study (60.5%). A total of 9 were survey screen-positive for HS, representing a prevalence of 0.9% (95% CI: 0.5%-1.7%).</p><p><strong>Conclusions: </strong>This single tertiary referral center study identified an HS prevalence of 0.9% in Australia. The methods address the deficiencies in other methodologies and provide insight into the prevalence of HS globally as part of the GHiSA initiative.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-5"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Hidradenitis Suppurativa Epidemiology: Exploring Themes and Gaps beyond Europe, Australia, and the USA.","authors":"Cecilia E Medianfar, Lauren I Fernandez, Dorra Bouazzi, Gregor B E Jemec","doi":"10.1159/000542389","DOIUrl":"10.1159/000542389","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Although a prevalence estimate has been proposed, this is based largely on studies from Europe, USA, and Australia. As literature on HS is scarce beyond these populations, our knowledge on epidemiology and clinical presentation from these areas are limited.</p><p><strong>Summary: </strong>A narrative literature search was conducted on the PubMed Medline database on November 6th, 2023, to examine HS epidemiological data from Asia, Latin America, North America, Africa, and Oceania, excluding articles from Europe, USA, and Australia. Relevant data (e.g., prevalence, gender distribution, age, smoking status) were extracted. A total of 26 articles were included: three from Africa, four from Latin America, one from North America, 18 from Asia, and none from Oceania. Prevalence varied widely, from 0.41% in Brazil to 3.2% in Greenland. Female predominance was noted in Latin America and Greenland, while male predominance was observed in Asia. Smoking rates varied significantly, from 0% in Ghana to 93.8% in Greenland.</p><p><strong>Key messages: </strong>(1) There is a notable lack in epidemiological HS data from large areas of the globe, particularly from Africa, Latin America, and Oceania. Further, significant heterogeneity in methodology and data reporting leads to inconsistencies in the comparability of the available data; (2) there are notable differences in gender distribution of HS across regions, with female predominance seen in Latin America and Greenland, while male predominance is more common in East Asia; (3) obesity and smoking, factors commonly described as risk factors for HS, where not consistently described across the studies, suggesting possible regional differences in risk factors; (4) it is crucial to encourage HS research globally to improve understanding, diagnosis, and treatment options for this significant disease.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hidradenitis Suppurativa in Skopje, North Macedonia.","authors":"Ivana Tusheva, Vesna Brishkoska Boshkovski, Dorra Bouazzi, Cecilia E Medianfer, Robin Christensen, Gregor B E Jemec, Vesna Trajkova, Irena Dimitrovska, Ana Ristovska-Dimitrovska, Katerina Damevska","doi":"10.1159/000539140","DOIUrl":"10.1159/000539140","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) exhibits varying prevalence globally, markedly influenced by geographical and ethnic distinctions. This study, part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aimed to assess the prevalence of HS in North Macedonia and contribute to the global epidemiology of this complex dermatological disorder.</p><p><strong>Methods: </strong>Conducted at City General Hospital \"8th September\" in Skopje, North Macedonia, from March 23, 2023, to May 30, 2023, this single-center study enrolled 597 healthy adults using a validated screening questionnaire. The participants were selected from accompanied outpatients and visitors of hospitalized patients in various departments, excluding the dermatology department. The questionnaire consisted of questions leading to the diagnosis of HS, particularly about the presence of boils, and it was administered as an interview by dermatology residents under the supervision of dermatologists. Participants who tested positive on the screening questionnaire were examined by dermatologists.</p><p><strong>Results: </strong>Out of 600 participants, 597 successfully completed the questionnaire (291 male and 301 female), and among them, 5 individuals (3 male and 2 female) were identified as having HS. This indicates an HS prevalence rate of 0.84%. Demographic analysis showed a male predominance in the HS group, with a median age of onset at 36 years (42.0 in the control group). Smoking and higher BMI were associated with HS. Notably, the study identified HS cases among participants initially screening negative, emphasizing the complexity of diagnosis. The diagnostic questionnaire demonstrated a sensitivity of 0.60 and a specificity of 0.84.</p><p><strong>Conclusion: </strong>This epidemiological study contributes to the global understanding of HS prevalence, demographic characteristics, and associated factors. With a rate of 0.84%, HS remains a significant concern. The observed male predominance in HS incidence deviates from global trends.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Prevalence of Hidradenitis Suppurativa.","authors":"Gabrielle R Vinding, Mohammed Saiful Islam Bhuiyan","doi":"10.1159/000542381","DOIUrl":"10.1159/000542381","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-2"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hidradenitis Suppurativa in Fars Province, Iran.","authors":"Farhad Handjani, Nasrin Saki, Mohammad Mahdi Parvizi, Roya Radanfar, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec","doi":"10.1159/000540422","DOIUrl":"10.1159/000540422","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a persistent and inflammatory skin condition that greatly diminishes the quality of life of the patients and frequently develops because of occlusion of the hair follicles. This study aimed to determine the prevalence of HS among the Iranian population residing in Fars province.</p><p><strong>Methods: </strong>This study was a cross-sectional study that was conducted at Shahid Faghihi Clinic at Shiraz University of Medical Sciences, Iran. The study included over 18-year-old healthy individuals who accompanied patients that had attended our center for non-dermatological care. The interviewers handed out a screening questionnaire on HS to the study participants, and then those individuals who were suspicious of having HS were examined by a dermatologist to verify if the individual has HS. The dermatologist also examined 10% of participants who reported no HS symptoms to reduce bias. The data analysis was conducted by using RStudio version 1.3.1093.</p><p><strong>Results: </strong>The results of our study indicated that 3 out of the 990 study participants suffered from HS, putting the prevalence of HS at 0.3% (95% CI: 0.10%-0.89%). After physically examining 3 questionnaire-positive HS individuals, we confirmed their assertion (sensitivity: 1.0). After screening 10% of the individuals negative for HS, the specificity was 0.83, positive predictive value was 0.13, and negative predictive value was 1. Moreover, this study found that the participants with and without HS had similar characteristics in terms of gender, age, and body mass index.</p><p><strong>Conclusion: </strong>It seems that the prevalence of HS in Iran is lower in comparison with many other countries. Gender, age, and BMI were similar in HS and non-HS participants. Future research is recommended to evaluate the other characteristics of this disease in Iran.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hidradenitis Suppurativa in Serbia: Validation of a Screening Questionnaire.","authors":"Ivana Jocic, Branko Dujovic, Lidija Kandolf, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec, Zeljko Mijuskovic","doi":"10.1159/000539877","DOIUrl":"10.1159/000539877","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by painful nodules and rupturing abscesses causing sinus tunnels and scarring, most commonly in the axilla, inguinal, perianal, and submammary areas. The global prevalence varies considerably, ranging from 0.00033% to 4.1%. To date, no epidemiological studies on HS have been conducted in Serbia. The aim of the study was to determine the prevalence of HS in Serbia.</p><p><strong>Methods: </strong>This research is a monocentric study initiated by the Global Hidradenitis Suppurativa Atlas (GHISA), conducted at the Military Medical Academy in Belgrade, and is part of the GHISA project. The study included healthy companions of the patients who filled out a validated questionnaire in the local language in which they reported their gender, age, weight, height, cigarette consumption, and the presence of painful nodules on the skin of the body folds. All people who reported having the changes defined in the questionnaire and every tenth person who said there were no changes were examined by experienced dermatologists and final year dermatology residents.</p><p><strong>Results: </strong>In the study, among 490 respondents, 4 were confirmed as HS, the point prevalence was 0.82%. HS was diagnosed equally in women and men. All patients had a BMI above normal, which is a known risk factor for HS. The affected regions in the HS group were the axilla and groin. The screening questionnaire had a sensitivity of 0.5 (2/4), a specificity of 0.93 (62/67), a positive predictive value of 0.29 (2/7), and a negative predictive value of 0.97 (62/64).</p><p><strong>Conclusion: </strong>The prevalence of HS in Belgrade, Serbia is 0.82%. The disease occurs equally frequently in both sexes. The HS screening questionnaire proves to be an appropriate instrument for population surveys.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Risk of Heart Failure among Patients with Bullous Pemphigoid: A Nationwide Cohort Study.","authors":"Tai-Li Chen, Wan-Ting Huang, Chen-Yi Wu, Ching-Hui Loh, Huei-Kai Huang, Ching-Chi Chi","doi":"10.1159/000547272","DOIUrl":"10.1159/000547272","url":null,"abstract":"<p><strong>Introduction: </strong>Bullous pemphigoid (BP) and heart failure (HF) share similar mechanisms involving chronic inflammation. Nevertheless, the association of BP with HF has been unclear. This study aimed to investigate the association of BP with incident HF.</p><p><strong>Methods: </strong>We conducted a nationwide cohort study included adults aged ≥20 years from Taiwan's National Health Insurance Research Database between 2011 and 2019. Adults with newly diagnosed BP and matched controls were included. A Cox regression model considering stabilized inverse probability weighting was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident HF in association with BP. Stratified analyses according to age and sex were conducted. Multiple sensitivity analyses were also performed.</p><p><strong>Results: </strong>Among 39,835 subjects, 975 patients in the BP cohort and 2,311 patients in the non-BP cohort developed HF, with incidence rates of 46.1 and 16.9 per 1,000 person-years, respectively. Adults with BP had a significantly increased risk of incident HF (HR 2.63; 95% CI 2.44-2.83) compared to those without BP. The association remained significant in the age- and sex-stratified analyses. Multiple sensitivity analyses confirmed the robustness of our primary analyses.</p><p><strong>Conclusion: </strong>BP is associated with an increased risk for HF. Early detection of HF and cardiology consultation among patients with BP presenting relevant symptoms may be implicated in the current practice.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidradenitis Suppurativa Prevalence in Indonesia: A Cross-Sectional Multicenter Study and Validation of a Screening Questionnaire.","authors":"Shinta Trilaksmi Dewi, Nyoman Suryawati, Niken Indrastuti, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec, Nisha S Chandran, Miranti Pangastuti, Aryani Adji, Gardenia Akhyar, Nopriyati Nopriyati, Cut Putri Hazlianda, Sri Awalia Febriana","doi":"10.1159/000539705","DOIUrl":"10.1159/000539705","url":null,"abstract":"<p><strong>Introduction: </strong>Studies on the prevalence of hidradenitis suppurative (HS) in Southeast Asia are scarce, and no studies have been conducted in Indonesia. This study aimed to calculate the prevalence of HS in Indonesia and validate this questionnaire in our population as part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative.</p><p><strong>Methods: </strong>This multicenter cross-sectional study was conducted at 7 teaching hospitals in western and central Indonesia from December 2022 to June 2023. A total of 3,237 healthy adults accompanying patients in the outpatient clinics consented to participate. Physicians or nurses delivered the validated screening questionnaire, and photos of the axilla and groin were taken from screen-positive individuals and 10% of the screen-negative individuals. The dermatologist examined the clinical photos to confirm the diagnosis of HS.</p><p><strong>Results: </strong>The prevalence of HS in our study population was 0.43% (14/3,237; with 95% confidence interval [CI]: 0.26%-0.72%), and there was no significant difference in gender, age, body mass index (BMI), and smoking habit between the HS and non-HS groups. In the HS group, males and females were equally affected, with the median age being 29 years with interquartile range (IQR: 24.8-38.5), median BMI of 23.0 (IQR: 21.1-26.4), and 28.6% being smokers. The screening questionnaire showed a sensitivity of 0.43 (6/14; 95% CI: 0.18-0.17), specificity of 0.94 (362/386; 95% CI: 0.91-0.96), positive predictive value of 0.20 (6/30; 95% CI: 0.08-0.39), and negative predictive value of 0.98 (362/370; 95% CI: 0.96-0.99).</p><p><strong>Conclusion: </strong>The prevalence of HS in Indonesia is 0.43%, slightly lower than those reported in other Southeast Asian countries. Age, gender, BMI, and smoking habits were not risk factors for HS in our population. The questionnaire is moderately accurate for screening HS but remains valuable in detecting around 50% of undiagnosed cases.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hidradenitis Suppurativa in Dhaka, Bangladesh: A Hospital-Based Study.","authors":"Mohammed Saiful Islam Bhuiyan, Towhida Noor, Sania Akhter, Nur-A-Tasmin Tahnin, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec","doi":"10.1159/000538444","DOIUrl":"10.1159/000538444","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of hidradenitis suppurativa (HS) varies widely in different epidemiologic studies from different parts of the world and very few data are available from South Asia.</p><p><strong>Objectives: </strong>The aim of this study was to determine the prevalence of HS in Dhaka, Bangladesh.</p><p><strong>Methods: </strong>An exploratory, cross-sectional, and descriptive study was done among 2,500 consecutive healthy accompanying adults of patients attending at the outpatient department (except dermatology), at the Bangabandhu Sheikh Mujib Medical University Hospital, Dhaka, Bangladesh. This was an initiative of Global Hidradenitis Suppurativa Atlas (GHiSA), and it therefore followed the approach previously published by Bouazzi et al. Results: Out of a total of 2,377 accompanying persons, 3 were diagnosed with HS. The point prevalence was 0.13% (CI: 0.04%-0.37%), sensitivity was 0.1 (3/3), specificity was 0.1 (23/23), positive predictive value positive predictive value (PPV) was 0.1 (3/3), and the negative predictive value was 0.1 (23/23). The median age of the HS patients was 45.0, and the median BMI was 28.0. All 3 confirmed HS were male.</p><p><strong>Conclusions: </strong>The prevalence of HS in Bangladesh is lower than in western countries and other GHiSA studies like Singapore, Ghana, and Greenland.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa.","authors":"Mercè Grau-Pérez, Cristina Ciudad, Alejandro Molina-Leyva, Antonio Martorell, Eva Vilarrasa, Sofía Haselgruber, José Carlos Pascual, Fernando Alfageme, Irene Albert, Juan Garcias-Ladaria, Francisco Javier Melgosa, Raquel Rivera, Minia Campos, Gemma Ochando, Ramón García-Ruiz","doi":"10.1159/000546647","DOIUrl":"10.1159/000546647","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic disease that causes painful skin lumps and scarring in the skin. In an important number of patients, the disease starts in adolescence. Adalimumab was the first biologic drug approved in adolescents with HS, yet approval was done on a model-based extrapolation from other diseases. Data regarding the effectiveness and safety of adalimumab in HS in this age group is lacking. Our objective was to describe the effectiveness and safety of adalimumab in adolescents with moderate-to-severe HS.</p><p><strong>Methods: </strong>Retrospective multicenter case series. HS units across Spain were invited to participate, including all patients starting adalimumab in adolescence. Demographic, clinical, and treatment-related characteristics were retrieved. Effectiveness was measured as the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at 6 months. Safety was assessed by means of quantification and description of side effects over time.</p><p><strong>Results: </strong>A total of 65 patients from 9 HS units were included. Mean age at adalimumab start was 15.5 years. A total of 76.9% of patients achieved HiSCR at 6 months. Side effects were observed in 7 patients, 3 of them requiring drug discontinuation, with full recovery. The adult dosage (80 mg every other week [EOW]/40 mg every week) was more frequently used. The median drug survival time for adalimumab was 5.6 years (25th percentile: 2.9 years), and the recommended adolescent dosage (40 mg EOW) was associated with a need for intensification (p < 0.001). The main limitations of the study are the lack of a comparison group and the retrospective design.</p><p><strong>Conclusion: </strong>Adalimumab showed a similar safety profile in adolescents with moderate-to-severe HS as in adults, with better effectiveness data.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}